Transition Bio has leveraged the experience of world-leading experts in microfluidics, cell imaging, and machine learning to establish a one-of-a-kind technology platform to revolutionize condensate drug discovery. We bring together science and technology to create novel therapeutics. Transition Bio combines first-of-its-kind microfluidic tools, cellular assays, and machine learning to explore chemical space – in vitro, in vivo & in silico – to discover new therapies for diseases driven by biomolecular condensates. 

Inside all our cells, many of the reactions that keep us alive happen within biomolecular condensates, non-membrane-bound structures containing proteins and genetic material.  Diseases can arise when these structures go awry.  Currently, there are no approved therapies targeted to specifically address these problems. Our platform helps us to more rapidly understand the properties of condensates compared with traditional screening methods, ultimately enabling a more efficient design of targeted therapeutics. 

We employ a multidimensional, high-throughput approach to studying the modulation of biomolecular condensates. Using our one-of-a-kind screening platform, we generate extensive behavioral datasets on the mechanisms of condensate modulation, which until now have been unavailable. We combine our cellular assays with state-of-the-art imaging and analytical techniques to unravel the effects of condensate modulators in bespoke cell lines and discover how molecules affect condensate formation at the cellular level. We study condensate composition and determine how condensates affect key cellular processes. This deep level of understanding enables us to determine the best condensate targets and the most appropriate interventions. Incorporating our unique datasets generated from our platform, we apply machine learning for target prediction and in-silico drug discovery.&a